Wire · operational-macro
FDA approves subcutaneous induction regimen of Skyrizi for Crohn's disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 October 2026 · Fusion42 review
The FDA has approved a subcutaneous induction regimen of Skyrizi (risankizumab) for adults with moderate to severe Crohn's disease, enabling patients to start induction therapy at home. This approval is based on phase 3 AFFIRM trial data demonstrating significantly higher clinical remission rates compared to placebo.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You can now offer home-based starter therapies for Crohn's disease with less reliance on hospital infusions. That opens a direct patient access route and reduces treatment friction you can exploit this week.
◆ Coverage
2 sources · 24 Oct 2026
◆ Related on Wire
◆ Topics